Can I read Final tolerance and acceptance results of a phase I/II clinical trial of permanent breast 103Pd seed implant on EtoBox?

Final tolerance and acceptance results of a phase I/II clinical trial of permanent breast 103Pd seed implant by Jean-Philippe Pignol; Eileen Rakovitch; Brian Keller; Raxa Sankreacha is a Medicine article available to read on EtoBox.

What is Final tolerance and acceptance results of a phase I/II clinical trial of permanent breast 103Pd seed implant about?

months (range 14e208 months). Median age at local recurrence (LR) was 56 years. 62% of the recurrences were 1 cm or less and 92% were ductal infiltrative carcinoma. With a median followup after the second conservative treatment of 81 months, the local control rate and breast conservation rate are 85% and 78% at 5 years respectively. Freedom from distant metastasis is 82%. The disease-free survival (DFS), the overall survival (OS) and the disease-specific survival (DSS) are respectively 72%, 92% and 95% at 5 years. Multivariate analysis showed two factors to be associated with a better local control, a recurrence size of 1cm or less (p 5 0,005) and the interval between primary breast cancer and LR 24 months or more (p 5 0,03). Factors associated with better DFS or DSS were no initial involvement of the axilla (p 5 0,001) and a recurrence size of 1cm or less (p 5 0,01). The most common late toxicities consisted of skin fibrosis and telangiectasia in 25% of the patients. Intermittent grade 1 pain is seen in 35% of the patients. Cosmetic results are good in 75% of the patients. Conclusions: Local tumor excision combined with HDR brachytherapy for small local-regional tumor recurrences

Who reads Final tolerance and acceptance results of a phase I/II clinical trial of permanent breast 103Pd seed implant?

Author

Jean-Philippe Pignol; Eileen Rakovitch; Brian Keller; Raxa Sankreacha

Publisher

Elsevier Science; Elsevier ; Elsevier BV (ISSN 1538-4721)

Published

2008

Language

EN

Field

Medicine (Health Sciences)